-
公开(公告)号：US11975070B2
公开(公告)日：2024-05-07
申请号：US16756785
申请日：2018-10-23
发明人： Oscar Wiklander , Andre Gorgens
IPC分类号： A61K39/395 , A61K35/55 , B01D15/38 , C07K14/70 , C07K14/705 , C07K14/71 , C07K14/715
CPC分类号： A61K39/395 , A61K35/55 , B01D15/3809 , C07K14/70596 , C07K14/7151 , C07K2319/30 , C07K2319/705
摘要： The present invention pertains to affinity chromatography isolation and purification of extracellular vesicles (EVs). The EVs of the present invention are engineered to enable highly specific binding to e.g. chromatography matrices, which is highly useful for affinity-based isolation and purification of EVs from complex biological fluids such as cell culture medium or biological fluids.
-
公开(公告)号：US11965013B2
公开(公告)日：2024-04-23
申请号：US17514743
申请日：2021-10-29
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号： C07K14/70 , A01N37/46 , A61K38/06 , A61K38/08 , A61K38/17 , A61K39/00 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/00 , C07K14/47 , C07K14/725 , C07K14/74 , C07K16/18 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N9/64 , C12Q1/6886 , G01N33/50 , G01N33/566 , G01N33/569 , A61K38/00
CPC分类号： C07K14/70539 , A01N37/46 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12Q1/6886 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , A61K38/00 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2501/998 , C12N2502/11 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要： A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
公开(公告)号：US11434274B2
公开(公告)日：2022-09-06
申请号：US17698426
申请日：2022-03-18
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号： C07K14/70 , C07K14/74 , A61K38/06 , C12N9/64 , C12N5/0783 , C07K16/30 , C07K14/47 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/00 , C07K7/06 , C07K7/02 , G01N33/50 , G01N33/566 , C07K16/18 , A61K38/08 , C07K14/725 , G01N33/569 , A61K38/17 , C12Q1/6886 , A01N37/46 , A61K38/00
摘要： A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
公开(公告)号：US10556941B2
公开(公告)日：2020-02-11
申请号：US16156521
申请日：2018-10-10
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , UNIVERSITÉ DE BORDEAUX , UNIVERSITÉ DE RENNES , ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP) , UNIVERSITÉ DES ANTILLES ET DE LA GUYANE , INSTITUT BERGONIÉ , UNIVERSITY OF NOTTINGHAM
发明人： Patrick Legembre , Pierre Vacher , Doriane Sanseau , Aubin Penna , Robin Flynn
IPC分类号： C07K14/70 , A61K38/00 , C07K14/705 , C07K14/525 , C07K16/00 , G01N33/68
摘要： The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.
-
公开(公告)号：US10202436B2
公开(公告)日：2019-02-12
申请号：US15917159
申请日：2018-03-09
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号： C07K14/70 , C07K14/74 , G01N33/569 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/725 , C12Q1/6886 , C07K14/47 , C07K16/30 , A61K38/08 , C07K7/02 , C07K7/06 , G01N33/566 , C07K16/18 , C12N5/0783 , C12N9/64 , C07K14/00 , A61K38/17 , G01N33/50 , A61K38/06 , A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10189887B2
公开(公告)日：2019-01-29
申请号：US15304550
申请日：2015-04-16
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE BORDEAUX , UNIVERSITÉ DE RENNES , ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP) , UNIVERSITÉ DES ANTILLES ET DE LA GUYANE , INSTITUT BERGONIÉ , UNIVERSITY OF NOTTINGHAM
发明人： Patrick Legembre , Pierre Vacher , Doriane Sanseau , Aubin Penna , Robin Flynn
IPC分类号： C07K14/70 , C07K16/00 , C07K14/705 , C07K14/525 , G01N33/68 , A61K38/00
摘要： The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.
-
公开(公告)号：US10138288B2
公开(公告)日：2018-11-27
申请号：US15789567
申请日：2017-10-20
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号： C07K14/70 , C07K14/74 , G01N33/569 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/725 , C12Q1/6886 , C07K14/47 , C07K16/30 , A61K38/08 , C07K7/02 , C07K7/06 , G01N33/566 , C07K16/18 , C12N5/0783 , C12N9/64 , C07K14/00 , A61K38/17 , G01N33/50 , A61K38/06
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10005828B2
公开(公告)日：2018-06-26
申请号：US15842381
申请日：2017-12-14
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号： C07K14/70 , C07K14/74 , C07K14/47 , C12N5/0783 , G01N33/569 , C12N9/64 , C07K14/00 , G01N33/50 , A61K38/17 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/725 , C12Q1/6886 , C07K16/30 , C07K7/06 , C07K7/02 , A61K38/08 , G01N33/566 , C07K16/18
CPC分类号： C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US09982031B2
公开(公告)日：2018-05-29
申请号：US15789589
申请日：2017-10-20
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号： C07K14/70 , C07K14/74 , G01N33/569 , A61K39/00 , C12N5/0783 , C07K16/30 , C07K14/00 , C07K16/18 , C07K7/06 , C12Q1/68 , G01N33/566 , A61K45/06 , A61K38/17 , G01N33/50 , C07K14/725 , C07K14/47 , C07K16/28 , C07K7/02 , A61K38/08 , C12N9/64 , A61K38/06
CPC分类号： C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
10.发明授权Regulation of specific spinal neurons regulating pain transmission via chimeric toxins 有权调节通过嵌合毒素调节疼痛传播的特定脊髓神经元公开(公告)号：US09447405B2
公开(公告)日：2016-09-20
申请号：US14181241
申请日：2014-02-14
申请人： Eric A. Johnson , Sabine Pellett , William H. Tepp , Tony L. Yaksh , Marc Marino , Qinghao Xu
发明人： Eric A. Johnson , Sabine Pellett , William H. Tepp , Tony L. Yaksh , Marc Marino , Qinghao Xu
IPC分类号： A61K38/16 , A61K39/08 , C07K14/33 , C12N9/96 , C07K7/22 , A61K47/48 , C07K14/575 , C07K14/70 , C07K14/72 , A61K38/48
CPC分类号： A61K47/62 , A61K9/0085 , A61K38/164 , A61K38/4893 , C07K7/22 , C07K14/33 , C07K14/57545 , C07K14/70 , C07K14/72 , C07K2319/01 , C07K2319/33 , C07K2319/55 , C12N9/96 , C12Y304/24069
摘要： A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.
摘要翻译： 公开了一种嵌合毒素，其包含特异性靶向涉及疼痛加工的神经元的肽配体; 和梭菌神经毒素轻链，其中所述配体与轻链连接。 还公开了制备这种嵌合毒素的方法和使用嵌合毒素调节疼痛传递的方法。
-
-
-
-
-
-
-
-
-
搜索结果
205 条记录 (耗时 0.05 秒)
